In addition to ibrutinib, patients with M-CLL, devoid of TP53 aberrations and suit more than enough to tolerate FCR therapy, should be fantastic candidates for the latter, With all the advantage remaining that this procedure might be finished in 6 months even though ibrutinib should be taken indefinitely. This option will be notably valuable for no